A PHASE 1, SINGLE DOSE OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF LORLATINIB IN SUBJECTS WITH IMPAIRED RENAL FUNCTION
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Lorlatinib (Primary)
- Indications Cancer; Lymphoma; Neuroblastoma; Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Nov 2019 Planned End Date changed from 9 Nov 2019 to 20 Mar 2020.
- 14 Nov 2019 Planned primary completion date changed from 18 Oct 2019 to 26 Feb 2020.
- 10 Sep 2019 Preliminary results (n=8) presented at the 20th World Conference on Lung Cancer